Skip to content


1 April 2017

Prime Minister Malcolm Turnbull has fulfilled the Coalition’s pledge to spend $54 million subsidising continuous glucose monitoring [CGM] for eligible Australians with Type 1 diabetes. The promise, originally made on 15 May 2016, will be fulfilled from 1 April 2017 for Australians under the age of 21 who meet specific criteria.

This decision reflects years of effort by members of the diabetes community. We congratulate everyone involved.

Funding will apply to Medtronic CGM products used with a Medtronic Insulin Pump or standalone CGM with the new Guardian ™ Connect

This is a positive first step in improving diabetes management within our community. However, we realise that it does not provide CGM to everyone and that it should be a continued priority of our community to improve access to all who may benefit. For people who are not eligible, Medtronic will continue to offer CGM subscriptions packages.

The eligibility criteria for the ‘CGM Initiative’ announced is available here and listed below.





CGM measures and indicates glucose levels continuously [24/7] to assist in monitoring. It can be used by type 1 and type 2 diabetes patients who would like better glucose control to improve the health and quality of their lives – and can help to take the guesswork out of glucose monitoring.

There are two ways patients can benefit from Medtronic CGM

  • With an insulin pump. With CGM and the Medtronic Veo or MiniMed 640G Insulin Pump, insulin delivery can be automatically stopped to reduce the occurrence or severity of hypoglycaemia1,2. Patients have the ability to set alerts to warn about highs or lows, and will see the full picture of glucose levels 24/7 on the device.
  • Without an insulin pump. Guardian™ Connect CGM delivers real-time glucose information direct to the user’s iOS device3. The user (and any care partners i.e. family members/carers or healthcare professionals) can be alerted if they’re heading towards hypoglycaemia or hyperglycaemia.

This is important because people who are hypo unaware are six times more likely to have severe hypoglycaemia leading to seizures, coma and even death.[i] Having hypos leads to more hypos and the increased risk of these severe events.

Medtronic have four products available through the CGM Initative; the Enlite™ Sensor, Guardian™ 2 Link, MiniLink transmitter, Guardian Connect™ CGM. CGM technology enables a user to monitor glucose levels 24 hours a day through a sensor.

The varieties of Medtronic CGM in Australia

CGM technology

[i] Prevalence of impaired awareness of hypoglycaemia in adults with Type 1 diabetes. Geddes J, Schopman JE, Zammitt NN, Frier BM. Diabet Med. 2008 Apr; 25(4):501-4

No comments yet

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: